Treatment of primary cutaneous CD30‐positive anaplastic large cell lymphoma with Wenyang Shengji decoction and Huanglian ointment: A case report

Abstract

Primary cutaneous CD30 positive anaplastic large cell lymphoma (PC‐ALCL) is a rare non‐Hodgkin's lymphoma. Combined chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), MACOP‐B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), or F‐MACHOP (5‐fluorouracil, methotrexate, cytosine‐arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone) are often used for its clinical treatment. In this study, we reported a new treatment method using a traditional Chinese therapy involving oral Wenyang Shengji decoction (WSD) combined with Huanglian ointment applied externally in a 32‐year‐old female patient with PC‐ALCL. Introduction: A 32‐year‐old woman who complained of an ulcer on the forehead accompanied by significant pain. PC‐ALCL was diagnosed by histopathological examination and immunohistochemical analysis. Treatment plan: WSD was prepared in 300 mL water and administered orally as a 150 mL decoction twice daily, and Huanglian ointment was applied to the ulcer three times daily. After 8 weeks of treatment with WSD combined with Huanglian ointment, the lesion healed completely. Immunohistochemical analysis revealed the presence of scattered CD3+++, CD4++, CD8++, CD20++, and CD30‐positive cells. After 12 weeks of treatment, the ulcer healed completely, leaving only a marked pale red‐ pitted scar. The patient was followed up for 3 years without recurrence and no adverse events. Conclusion: oral WSD combined with Huanglian ointment applied to the ulcer for PC‐ALCL can promote the healing of ulcers, reduce or alleviate the formation of scar, and eliminate CD30‐positive cells. This case report provides a reference for the clinical treatment of PC‐ALCL using traditional Chinese medicine.

Keywords

Huanglian ointment / primary cutaneous CD30 positive anaplastic large cell lymphoma / therapeutics / traditional Chinese medicine / Wenyang Shengji decoction

References

[1] Gleason L, Afifi L, Banner L, et al. Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma. Mol Clin Onco. 2024; 20 (5): 35.

[2] Chen J, Martinez A, Shinohara MM, et al. Risk of systemic lymphoma in patients with cutaneous CD30+ lymphoproliferative disorders: a single center retrospective cohort analysis. J Am Acad Dermatol, 2024; 91 (1): 134- 135.

[3] Tagami T, Alhalabi O, Ward N, Huang, J. Paraneoplastic dermatosis in a patient with anaplastic large-cell lymphoma: case report and literature review. Dermatopathology 2016; 3 (2): 39- 43.

[4] Xu H, Liu Q, Li YM, Hu, H. Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma. Dermatol Ther. 2019; 32 (2): e12834.

[5] Baik BS, Lee WS, Ji SY, Park, KS, Yang, WS, Kim, SY. Treatment of primary cutaneous anaplastic large cell lymphoma. Arch Craniofac Surg. 2019; 20 (3): 207- 211.

[6] Oliveira LS, Nobrega MP, Monteiro MG, Almeida, WLd. Primary cutaneous anaplastic large-cell lymphoma-case report. An Bras Dermatol. 2013; 88 (6 Suppl 1): 132- 135.

[7] Su PH, Tai CJ. Current development in integrative therapy of traditional Chinese medicine for cancer treatment: a mini-review. J Tradit Complement Med. 2019; 10 (5): 429- 433.

[8] Gao Y, Chen S, Sun J, et al. Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: a review. Phytother Res. 2021; 35 (2): 603- 628.

[9] Samadi P, Sarvarian P, Gholipour E, et al. Berberine: a novel therapeutic strategy for cancer. IUBMB Life 2020; 72 (10): 2065- 2079.

[10] Chandrasiri N, Taiwo O, Ahmed M, et al. Undifferentiated pleomorphic sarcoma mimicking breast implant-associated anaplastic large cell lymphoma. J Breast Cancer. 2024; 27 (3): 215- 222.

[11] Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96 (12): 3681- 3695.

[12] Mu HX, Tang XQ. Primary cutaneous anaplastic large cell lymphoma with over-expressed Ki-67 transitioning into systemic anaplastic large cell lymphoma: a case report. World J Clin Cases. 2023; 11 (28): 6889- 6894.

[13] Wu R, Lim MS. Updates in pathobiological aspects of anaplastic large cell lymphoma. Front Oncol. 2023; 13: 1241532.

[14] Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118 (15): 4024- 4035.

[15] Duvic M, Tetzlaff MT, Gangar P, Clos, AL, Sui, D, Talpur, R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015; 33 (32): 3759- 3765.

[16] Song Z, Wu W, Wei W, et al. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma. Blood. 2023; 142 (15): 1297- 1311.

[17] Gao T, Bi H, Ma S, Lu, J. The antitumor and immunostimulating activities of water soluble polysaccharides from radix aconiti, radix aconiti lateralis and radix aconiti kusnezoffii. Nat Prod Commun. 2010; 5 (3): 447- 455.

[18] Yang X, Wu Y, Zhang C, Fu, S, Zhang, J, Fu, C. Extraction, structural characterization, and immunoregulatory effect of a polysaccharide fraction from Radix Aconiti Lateralis Preparata (Fuzi). Int J Biol Macromol. 2020; 143: 314- 324.

[19] Li H, Sun M, Xu J, Zang, M, Cui, Y. Immunological response in H22 transplanted mice undergoing Aconitum coreanum polysaccharide treatment. Int J Biol Macromol. 2013; 55: 295- 300.

[20] Zhang Z, Li M, Wang Y, Wu, J, Li, J. Higenamine promotes M2 macrophage activation and reduces Hmgb1 production through HO-1 induction in a murine model of spinal cord injury. Int Immunopharm. 2014 Dec; 23 (2): 681- 687.

[21] Chen XP, Li W, Xiao XF, Zhang, LL, Liu, CX. Phytochemical and pharmacological studies on Radix Angelica sinensis. Chin J Nat Med. 2013 Nov; 11 (6): 577- 587.

[22] Patyra A, Vaillé J, Omhmmed S, et al. Pharmacological and phytochemical insights on the pancreatic β-cell modulation by Angelica L. roots. J Ethnopharmacol. 2024 Jul 15; 329: 118133.

[23] Jo GH, Kim SN, Kim MJ, Heo, Y. Protective effect of Paeoniae radix alba root extract on immune alterations in mice with atopic dermatitis. J Toxicol Environ Health. 2018; 81 (12): 502- 511.

[24] Pang B, Chen Z, Xing YQ. Effects of paeoniflorin modulating RhoA/ROCK signaling pathway on Th17/Treg immune balance in mice with experimental autoimmune uveitis. New Chinese medicine and clinical pharmacology. 2024; 35 (4): 506- 512 (in Chinese).

[25] Yamakawa H, Ito Y, Naganawa T, et al. Activation of caspase-9 and -3 during H2O2-induced apoptosis of PC12 cells independent of ceramide formation. Neurol Res. 2000; 22 (6): 556- 564.

[26] Zhang DF. The application effect of Huanglian ointment in the nursing of patients with chronic skin ulcers and its influence on patient satisfaction. Today Nurse. 2018; 25 (08): 150- 152 (in Chinese).

RIGHTS & PERMISSIONS

2024 The Author(s). Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.